What are NCCN treatment guidelines for early-stage, unfavorable Hodgkin lymphoma (Hodgkin disease)?

Updated: Sep 12, 2018
  • Author: Bradley W Lash, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Currently, the National Comprehensive Cancer Network (NCCN) supports the following treatments [4] :

  • Early-stage unfavorable, no bulky mediastinal disease: ABVD regimen for two cycles (initially with staging and additional ABVD cycles as warranted) or  Stanford V regimen or escalated BEACOPP for two cycles + ABVD for two cycles +ISRT

  • Early-stage unfavorable, with bulky mediastinal disease: ABVD for four cycles followed by ISRT (category 1 recommendation) or  Stanford V regimen for three cycles (12 weeks) + ISRT or escalated BEACOPP for two cycles + ABVD for two cycles +ISRT

Ongoing trials will determine if irradiation is needed. Currently, radiation is an important part of therapy, and it is mandatory with the Stanford V regimen.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!